On the determinants and the role of the payers in the uptake of genetic testing and data sharing in personalized health.

Background: New health technologies and data offer tailored prevention and spot-on treatments, which can considerably reduce healthcare costs. In healthy individuals, insurers can participate in the creation of health capital through data and preventing the occurrence of a disease. In the onset of a disease, sequencing an individual's genome can provide information leading to the use of more efficient treatments.

Is there a "pandemic effect" on individuals' willingness to take genetic tests?

In this cross-sectional, semi-longitudinal and quasi-experimental study, our goal was to determine the effect of data storage conditions on willingness to take a genetic test. We compared individuals' preferences regarding how they want to store health data collected from genetic tests through two survey experiments fielded in Switzerland in March 2020 and January 2022. We tested for differences whether genetic data are presented as private goods or public goods.

On Portfolios of Preventive Decisions for Multiple Health Risks - Evidence from US-Based Data.

Individuals face multiple health risks and therefore can undertake many preventive activities simultaneously, thus creating a portfolio of preventive activities. In this article, we first investigate the determinants likely to influence the composition of portfolios of preventive activities. Second, we look at the interactions between preventive activities.